KEY FEATURES
| Full Name | Calpain 1 |
|---|---|
| Synonym | PIG30; CANPL1; MuCANP; MuCL; Calpain 1, Large Subunit; Calpain-1 Catalytic Subunit; Calcium-Dependent Protease 1; Calcium-activated neutral proteinase 1; Calpain mu-type; Micromolar-calpain |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 1.56-100ng/mL |
| Sensitivity | 0.58ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human CAPN1 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human CAPN1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human CAPN1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human CAPN1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human CAPN1. You can calculate the concentration of Human CAPN1 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES
TYPICAL DATA
Human CAPN1 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 5.07 | 11.17 | 46.05 | 4.57 | 11.74 | 43.16 |
| Standard deviation | 0.35 | 0.59 | 1.61 | 0.23 | 0.65 | 2.17 |
| CV(%) | 6.96 | 5.3 | 3.49 | 5.01 | 5.54 | 5.02 |
RECOVERY
The recovery of Human CAPN1 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 92-108 | 98 |
| EDTA plasma (n=8) | 88-98 | 93 |
| Cell culture media (n=8) | 84-97 | 91 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human CAPN1 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.
Products associated with NR2B ELISA Kits
| GRIN1 antibody | publications with NR2B and GRIN1 |
| GRIN3A antibody | publications with NR2B and GRIN3A |
| SYNGAP1 antibody | publications with NR2B and SYNGAP1 |
| PRKCG antibody | publications with NR2B and PRKCG |
| PRKCA antibody | publications with NR2B and PRKCA |
| PLCG1 antibody | publications with NR2B and PLCG1 |
| PARK2 antibody | publications with NR2B and PARK2 |
| FYN antibody | publications with NR2B and FYN |
| DLG4 antibody | publications with NR2B and DLG4 |
| CAMK2A antibody | publications with NR2B and CAMK2A |
Pathways associated with NR2B ELISA Kit
| Activation Of NMDA Receptor Upon Glutamate Binding And Postsynaptic Events Pathway | Activation Of NMDA Receptor Upon Glutamate Binding And Postsynaptic Events Pathway |
| Alcoholism Pathway | Alcoholism Pathway |
| Alzheimer's Disease Pathway | Alzheimer's Disease Pathway |
| Alzheimers Disease Pathway | Alzheimers Disease Pathway |
| Amphetamine Addiction Pathway | Amphetamine Addiction Pathway |
| Amyotrophic Lateral Sclerosis (ALS) Pathway | Amyotrophic Lateral Sclerosis (ALS) Pathway |
Diseases associated with NR2B ELISA Kit
| Schizophrenia | publications with NR2B and Schizophrenia |
| Nervous System Diseases | publications with NR2B and Nervous System Diseases |
| Brain Diseases | publications with NR2B and Brain Diseases |
| Substance-Related Disorders | publications with NR2B and Substance-Related Disorders |
| Movement Disorders | publications with NR2B and Movement Disorders |
| Child Development Disorders, Pervasive | publications with NR2B and Child Development Disorders, Pervasive |
| Neoplasms | publications with NR2B and Neoplasms |
| Cognition Disorders | publications with NR2B and Cognition Disorders |
| Anxiety Disorders | publications with NR2B and Anxiety Disorders |
| Neurobehavioral Manifestations | publications with NR2B and Neurobehavioral Manifestations |
Organs/Tissues associated with NR2B ELISA Kit
| Brain | publications with NR2B and Brain |
